Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

Alebund (礼邦生物) Pre-IPO Quick Take: A Niche Renal Specialist

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Alebund Pharmaceuticals Jiangsu / Equity Capital Markets

<ul>
<li>Alebund Pharmaceuticals, a China-based clinical-stage biotech company, is looking to raise at least USD 100 million via a Hong Kong listing. Jefferies, BoA, and HTSC are the joint sponsors.</li>
<li>In our previous note, we looked at the company’s history and its core product, AP301, and AP306, and its management.</li>
<li>In this note, we look at the core product AP301’s pivotal Phase 3 data for AP301 presented in ASN2025.</li>
</ul>


Alebund Pharmaceuticals, a China-based clinical-stage biotech company, is looking to raise at least USD 100 million via a Hong Kong listing. Jefferies, BoA, and HTSC are the joint sponsors.
In our previous note, we looked at the company’s history and its core product, AP301, and AP306, and its management.
In this note, we look at the core product AP301’s pivotal Phase 3 data for AP301 presented in ASN2025.


Alebund (礼邦生物) Pre-IPO: Core Product AP301 Phase 3 Update